» Articles » PMID: 12502811

A Protective Role of Locally Administered Immunostimulatory CpG Oligodeoxynucleotide in a Mouse Model of Genital Herpes Infection

Overview
Journal J Virol
Date 2002 Dec 28
PMID 12502811
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Unmethylated CpG dinucleotides in bacterial DNA or synthetic oligodeoxynucleotides (ODNs) are known as potent activators of the immune system and inducers of several Th1-associated immunomodulatory cytokines. We therefore investigated whether such a CpG-containing ODN (CpG ODN) given mucosally in the female genital tract could enhance innate immunity and protect against genital herpes infection. Groups of C57BL/6 mice were treated intravaginally with either CpG ODN or a non-CpG ODN control in the absence of any antigen either 2 days before or 4 h after an intravaginal challenge with a normally lethal dose of herpes simplex virus type 2 (HSV-2). Mice treated with CpG ODN exhibited significantly decreased titers of HSV-2 in their vaginal fluids compared with non-CpG ODN-treated mice. Furthermore, CpG ODN pretreatment significantly protected against development of disease and death compared to non-CpG ODN pretreatment. Most strikingly, CpG ODN conferred protection against disease and death even when given after the viral challenge. The CpG ODN-induced protection was associated with a rapid production of gamma interferon (IFN-gamma), interleukin-12 (IL-12), IL-18, and RANTES in the genital tract mucosa following CpG ODN treatment. The observed protection appeared to be dependent on IFN-gamma, IL-12, IL-18, and T cells, as CpG ODN pretreatment did not confer any significant protection in mice deficient in IFN-gamma, IL-12, IL-18, or T cells. Further, a complete protective immunity to reinfection was elicited in CpG ODN-treated, HSV-2-challenged mice, suggesting a role for mucosally administered CpG ODN in inducing the development of an acquired immune response in addition to its potent stimulation of innate immunity.

Citing Articles

In Vitro Effect of 9,9'-Norharmane Dimer against Herpes Simplex Viruses.

Gonzalez M, Vizoso-Pinto M, Erra-Balsells R, Gensch T, Cabrerizo F Int J Mol Sci. 2024; 25(9).

PMID: 38732185 PMC: 11084892. DOI: 10.3390/ijms25094966.


Immunostimulation of Asian elephant () blood cells by parapoxvirus ovis and CpG motif-containing bacterial plasmid DNA upregulates innate immune gene expression.

Haycock J, Maehr T, Dastjerdi A, Steinbach F Front Immunol. 2024; 15:1329820.

PMID: 38590526 PMC: 10999609. DOI: 10.3389/fimmu.2024.1329820.


MyD88-dependent signaling drives toll-like receptor-induced trained immunity in macrophages.

Owen A, Luan L, Burelbach K, McBride M, Stothers C, Boykin O Front Immunol. 2022; 13:1044662.

PMID: 36439136 PMC: 9692127. DOI: 10.3389/fimmu.2022.1044662.


A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination Against .

Sun P, Li X, Pan C, Liu Z, Wu J, Wang H Front Immunol. 2022; 13:884555.

PMID: 35493470 PMC: 9043751. DOI: 10.3389/fimmu.2022.884555.


Vaginal delivery of vaccines.

VanBenschoten H, Woodrow K Adv Drug Deliv Rev. 2021; 178:113956.

PMID: 34481031 PMC: 8722700. DOI: 10.1016/j.addr.2021.113956.


References
1.
Jeansson S, Forsgren M, Svennerholm B . Evaluation of solubilized herpes simplex virus membrane antigen by enzyme-linked immunosorbent assay. J Clin Microbiol. 1983; 18(5):1160-6. PMC: 272860. DOI: 10.1128/jcm.18.5.1160-1166.1983. View

2.
Corey L, Langenberg A, Ashley R, Sekulovich R, Izu A, Douglas Jr J . Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA. 1999; 282(4):331-40. DOI: 10.1001/jama.282.4.331. View

3.
Harandi A, Svennerholm B, Holmgren J, Eriksson K . Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J Virol. 2001; 75(14):6705-9. PMC: 114395. DOI: 10.1128/JVI.75.14.6705-6709.2001. View

4.
Harandi A, Svennerholm B, Holmgren J, Eriksson K . Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-gamma-dependent RANTES production following a vaginal viral challenge. Am J Reprod Immunol. 2002; 46(6):420-4. DOI: 10.1034/j.1600-0897.2001.d01-34.x. View

5.
Wagner H . Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol. 2002; 5(1):62-9. DOI: 10.1016/s1369-5274(02)00287-4. View